Market Overview
The
U.S. Vaccine Market is expected to reach a value of
USD 82.9 billion by the end of 2024 which is further expected to reach a projection of
USD 105.4 billion in 2033 at a
CAGR of 2.7% in the
forecasted period of 2024 to 2033.
The growing incidences of numerous diseases such as influenza, Zika, and Ebola are becoming a growth driver for the U.S. Vaccine Market. The pharmaceutical industry is major as well-known pharmaceutical organizations focused on advanced studies and the development of the latest products centered around this region. The fundamental gamers in the mRNA vaccine production area are using the mRNA tech for vaccine formulation improvement which plays a considerable role in the growth of this market.
The presence of
SARS-COV-2 has further expanded this trend, and the market has been increasing step by step because of the rise in the need for efficacious vaccines to lower morbidity & mortality rates. As efforts to create successful vaccines commenced, mRNA generation turned into used to quickly modify vaccine sequencing so that it could be effective against the new virus's mutations, which fueled the market's expansion.
Key Takeaways
- Vaccines are anticipated to dominate the U.S. Vaccine Market in terms of type as it holds 77.1% of the market share in 2024.
- Hospitals are projected to dominate the U.S. vaccine market based on end users with 56.9% of the market share by the end of 2024.
- The U.S. Vaccine Market size is estimated to have a value of USD 82.9 billion in 2024 and is expected to reach USD 105.4 billion by the end of 2033.
- The market is growing at a CAGR of 2.7 % over the forecasted period.
Use Cases
- In the Prevention of Infectious Diseases: Vaccines are used for the prevention and eradication of various infectious diseases like influenza, polio, and hepatitis.
- Immunization in Childhood: This market offers many childhood immunization vaccines like MMR (Measles, Mumps, Rubella), DTaP (Diphtheria, Tetanus, Pertussis), and Varicella (Chickenpox) which are used at a certain age to develop a resistance against various diseases.
- Disease Control: Vaccines aid in controlling diseases like measles and polio in the U.S. and in global efforts to eradicate diseases like malaria and tuberculosis.
- Vaccination Campaigns: The U.S. vaccine market funds campaigns promoting vaccination awareness, and targeting specific populations for equal access to various vaccination programs.
Market Dynamic
The COVID-19 pandemic became one of the fundamental elements that pushed the growth of the vaccine market in the United States. It may be understood with the aid of the report posted via the World Health Organization in January 2020 which revealed that the mortality rate inside the US was 129,408 deaths in opposition to 2,833,552 cases. This vicinity fosters a properly-evolved pharmaceutical and healthcare infrastructure which pushes the growth of this marketplace. The drug market and method of vaccination are under complete control by the US government with the aid of the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) making ensure safety and satisfaction.
The disease prevalence and outbreaks such as flu, measles, and coronavirus determine the vaccination policy and demand. Government programs, like the Vaccines for Children (VFC) program and the Advisory Committee on Immunization Practices (ACIP), are the ones that are extremely important in vaccine production and marketing and are directed toward the increase in the number of vaccinated people, solving coverage disparities across racial and demographics groups.
Research Scope and Analysis
By Product Type
In the context of the type of vaccine that dominates the U.S. Vaccine Market, it holds 77.1% of the market share in 2024.
One of the most important reasons behind the dominance of these vaccines is the U.S. government promotes human health through its aggressive investment strategy in preventing and controlling infectious diseases via human vaccines. Diseases like influenza, measles, mumps, rubella, polio, HPV, and hepatitis have been targeted with extensive research, which in turn contributes to fall rates in morbidity and mortality.
The Food and Drug Administration (FDA) and governmental agencies play a role of importance when ensuring the safety standards and efficacy of Vaccines, this strengthens the level of confidence and boosts the popularity of the human vaccines. National immunization programs and CDC guidelines drive vaccine uptake alongside mandates for school, work, healthcare, and travel that further emphasize their role in the U.S. healthcare system.
By End User
Based on end users, hospitals are projected to dominate the U.S. vaccine market, holding 56.9% of the market share by the end of 2024.
Hospitals are multipurpose healthcare facilities that provide diverse medical services ranging from emergency care to transplanting diversified conditions. Hospitals are located in strategic areas like cities and suburbs, hence their proximity and accessibility are determined by the population size in the surrounding communities. Being near the hospital allows ease of access for patients, who may schedule the vaccination on the occasion of their regular hospital visits or even as part of other medical consultations.
Among the members of the medical workforce of hospitals, you can still find people having an entire variety of expert know-how and qualifications, together with physicians, nurses, pharmacists, and clinical document librarians who aid the patients in case of confusion about vaccination. Hospitals are places where patients are served by the maximum trusted healthcare experts, and the self-belief of patients is the principal factor of their vaccination acceptance.
The U.S. Vaccine Market Report is segmented on the basis of the following:
By Product Type
- Human Vaccine
- Pediatric Vaccines
- Adult & Adolescent vaccines
- Others
- Animal Vaccine
- Livestock Vaccine
- Companion Animal Vaccines
- Others
By End User
- Hospital
- Clinics
- Vaccination Centers
Competitive Landscape
In the United States, major pharmaceutical companies like Pfizer, Merck, and others such as Sanofi Pasteur are working on a broad spectrum of vaccines meant to protect people from a range of diseases such as influenza, coronavirus, and severe flu. The last one is Johnson & Johnson as an example, which manufactures only single-dose COVID-19 vaccine. AstraZeneca and Novavax are the pharma which are developing vaccines for a vast majority of chronic diseases.
The varyingly owned organizations, spread from public to private and from health clinics to emergency departments are all part of this interconnected chain and all play an integral role in the expansion of the US vaccine market. CDC and NIH share the responsibility of the research and immunization delivery in this sector. Non-profit and for-profit academic organizations and research centers are making vaccines and improving them aside from the fact that they are manufacturing them. Such companies have joined hands to fight diseases by way of immunizing people, making a joint effort to ensure that people are protected from any future ailments through health.
Some of the prominent players in the U.S. Vaccine Market are:
- GlaxoSmithKline Plc
- Merck & Company Incorporated
- Pfizer Incorporated
- AstraZeneca plc
- Sanofi Pasteur
- Boehringer Ingelheim
- Bharat Biotech.
- BIO-MEDSerum Institute of India Pvt. Ltd.
- Kedrion Biopharma Inc.
- GlaxoSmithKline plc.
- Other Key Players
Recent Development
- In February 2024, Moderna increased its U.S. COVID-19 vaccine market share, leading to a gain in subsequent profit despite a global revenue decline.
- In October 2022, A collaboration was formed between Merck & Co. Inc. and Moderna to pay more attention to their research and development activities & use their infrastructure to commercialize the personalized cancer vaccine named mRNA-4157/V940.
- In August 2022, Affinivax Inc. was acquired by GlaxoSmithKline Plc so that it can have access to their next generation 24-valent pneumococcal vaccine plan.
- In April 2022, GlaxoSmithKline submitted a BLA to the USFDA for the PRIORIX vaccine. Over 100 nations licensed it after Germany's initial registration.
- In January 2022, An agreement was formed between Germany-based BioNTech and Pfizer Inc. for the development of mRNA-based Shingles Vaccine for prevention of this deadly disease.
Report Details
| Report Characteristics |
| Market Size (2024) |
USD 82.9 Bn |
| Forecast Value (2033) |
USD 105.4 Bn |
| CAGR (2023-2032) |
2.7% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Product Type (Human Vaccine, and Animal Vaccine), By End User (Hospital, Clinics, and Vaccination Centers) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, Sanofi Pasteur, Boehringer Ingelheim, Bharat Biotech., BIO-MEDSerum Institute of India Pvt. Ltd., Kedrion Biopharma Inc., GlaxoSmithKline plc., and Other Key Players |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The U.S. Vaccine Market size is estimated to have a value of USD 82.9 billion in 2024 and is expected to reach USD 105.4 billion by the end of 2033.
Some of the major key players in the U.S. Vaccine Market are GlaxoSmithKline Plc, Merck & Company Incorporated, Pfizer Incorporated, AstraZeneca plc, and many others.
The market is growing at a CAGR of 2.7 percent over the forecasted period.
Contents
1.1.Objectives of the Study
1.3.Market Definition and Scope
2.U.S. Vaccine Market Overview
2.1.Global U.S. Vaccine Market Overview by Type
2.2.Global U.S. Vaccine Market Overview by Application
3.U.S. Vaccine Market Dynamics, Opportunity, Regulations, and Trends Analysis
3.1.1.U.S. Vaccine Market Drivers
3.1.2.U.S. Vaccine Market Opportunities
3.1.3.U.S. Vaccine Market Restraints
3.1.4.U.S. Vaccine Market Challenges
3.2.Emerging Trend/Technology
3.4.PORTER'S Five Forces Analysis
3.6.Opportunity Map Analysis
3.11.Supply/Value Chain Analysis
3.12.Covid-19 & Recession Impact Analysis
3.13.Product/Brand Comparison
4.Global U.S. Vaccine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By Product Type, 2017-2032
4.1.Global U.S. Vaccine Market Analysis by By Product Type: Introduction
4.2.Market Size and Forecast by Region
5.Global U.S. Vaccine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by By End User, 2017-2032
5.1.Global U.S. Vaccine Market Analysis by By End User: Introduction
5.2.Market Size and Forecast by Region
10.Global U.S. Vaccine Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2017-2032
10.1.1.North America U.S. Vaccine Market: Regional Analysis, 2017-2032
10.2.1.Europe U.S. Vaccine Market: Regional Trend Analysis
10.3.1.Asia-Pacific U.S. Vaccine Market: Regional Analysis, 2017-2032
10.3.1.7.Rest of Asia-Pacifc
10.4.1.Latin America U.S. Vaccine Market: Regional Analysis, 2017-2032
10.4.1.5.Rest of Latin America
10.5.Middle East and Africa
10.5.1.Middle East and Africa U.S. Vaccine Market: Regional Analysis, 2017-2032
11.Global U.S. Vaccine Market Company Evaluation Matrix, Competitive Landscape, Market Share Analysis, and Company Profiles
11.1.Market Share Analysis
11.3.2.Financial Highlights
11.3.5.Key Strategies and Developments
11.4.2.Financial Highlights
11.4.5.Key Strategies and Developments
11.5.Merck & Company Incorporated
11.5.2.Financial Highlights
11.5.5.Key Strategies and Developments
11.6.2.Financial Highlights
11.6.5.Key Strategies and Developments
11.7.2.Financial Highlights
11.7.5.Key Strategies and Developments
11.8.2.Financial Highlights
11.8.5.Key Strategies and Developments
11.9.Boehringer Ingelheim
11.9.2.Financial Highlights
11.9.5.Key Strategies and Developments
11.10.2.Financial Highlights
11.10.3.Product Portfolio
11.10.5.Key Strategies and Developments
11.11.BIO-MEDSerum Institute of India Pvt. Ltd.
11.11.2.Financial Highlights
11.11.3.Product Portfolio
11.11.5.Key Strategies and Developments
11.12.Kedrion Biopharma Inc.
11.12.2.Financial Highlights
11.12.3.Product Portfolio
11.12.5.Key Strategies and Developments
11.13.GlaxoSmithKline plc.
11.13.2.Financial Highlights
11.13.3.Product Portfolio
11.13.5.Key Strategies and Developments
11.14.2.Financial Highlights
11.14.3.Product Portfolio
11.14.5.Key Strategies and Developments
12.Assumptions and Acronyms